US · Healthcare · Biotechnology
EPS came in at -1.19 against a street estimate of -0.93 — a miss of 28.0%.
Analysts rate Rapport Therapeutics, Inc. Common Stock a strong buy (13 buy, 0 hold, 0 sell out of 13) with an average price target of $63.04.
| Fund | Stake |
|---|---|
| FMR Inc | 14.95% |
| TRV GP V, LLC | 13.09% |
| ARCH VENTURE CORP | 7.77% |
| The Goldman Sachs Group Inc | 6.13% |
| Capital Research & Mgmt Co - Division 3 | 6.09% |
| BlackRock Inc | 5.63% |
| Cormorant Asset Management, LLC | 5.54% |
| Sofinnova Ventures | 3.97% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 RAPPORT THERAPEUTICS, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $63.6 million in cash and cash equivalents plus $372.5 million | 2026-08-05 |
| Results announced · Q3 2026 RAPPORT THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Net loss for Q2 2026: $56.6 million (versus $26.7 million in Q2 2025) • Cash posit | 2026-08-05 |
| Shareholder vote results · Q2 2026 RAPPORT THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Outstanding shares: 47,807,623 common shares as of April 14, 2026 (record date) • Stock | 2026-06-10 |
| Quarterly report · Q1 2026 RAPPORT THERAPEUTICS, INC. - 10-Q SUMMARY Q1 2026 (Quarter Ended March 31, 2026) --- HEADLINE NUMBERS • Cash and Short-term Investments: $476.8 mil | 2026-05-07 |
| Results announced · Q2 2026 RAPPORT THERAPEUTICS - Q1 2026 SUMMARY HEADLINE NUMBERS • Net Loss: $19.9 million for Q1 2026 versus $24.1 million in Q1 2025 (18% improvement) • Co | 2026-05-07 |
| Proxy statement · Q2 2026 RAPPORT THERAPEUTICS, INC. – 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class II Directors to serve until 2029 ann | 2026-04-23 |
| Reg FD disclosure · Q2 2026 RAPPORT THERAPEUTICS, INC. — 8-K SUMMARY (April 21, 2026) HEADLINE NUMBERS • RAP-219 Phase 2a trial in focal onset seizures (FOS) showed 80% median | 2026-04-21 |
| Annual report FY2025 RAPPORT THERAPEUTICS, INC. - 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Rapport Therapeutics, Inc. (Nasdaq: RAPP), clinical-stage | 2026-03-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rapport Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.